Baidu
map

Br J Cancer:前列腺癌组织代谢物中精胺浓度和tChoCre/Spm比值具有术前风险评估价值

2017-10-23 MedSci MedSci原创

前列腺切除标本中精胺浓度和tChoCre/Spm比值是复发的独立预后标志物。

背景:前列腺癌患者高危复发风险的健康生物标志物的鉴别对于癌症护理具有很大的作用。这项研究调查了HR-MAS MRS可检测到的组织代谢物是否与根治性前列腺切除术后的复发相关。

方法:研究人员进行了回顾性离体研究,使用HR-MAS MRS对2002年至2010年期间收集的来自三个不同挪威队列的110例根治性前列腺切除患者的组织样本进行检测。在分析时,有50例患者出现前列腺癌复发。使用Cox比例风险回归模型,Kaplan-Meier生存分析和一致指数(C-index)评估代谢物,临床病理变量和无复发生存之间的关联。

结果:肿瘤内高精胺和柠檬酸盐浓度与无复发生存时间延长相关,而总胆碱+肌酸/精胺(tChoCre/Spm)和总胆碱+肌酸/柠檬酸盐(tChoCre/Cit)比率升高与复发时间较短有关。调整临床相关危险因素后,精胺浓度和tChoCre/Spm与多因素Cox比例风险模型复发率独立相关(C指数:0.769;HR:0.72;P = 0.016和C指数:0.765;HR:1.43;P = 0.014)。

结论:前列腺切除标本中精胺浓度和tChoCre/Spm比值是复发的独立预后标志物。这些代谢物可以在体内进行非侵入性测量,因此对于建立术前风险评估标准图具有预测价值。

原始出处:

本文系梅斯医学(MedSci)原创翻译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1659957, encodeId=d9a3165995e07, content=<a href='/topic/show?id=24e82545262' target=_blank style='color:#2F92EE;'>#代谢物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25452, encryptionId=24e82545262, topicName=代谢物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1225086772, createdName=旅苦化文_216, createdTime=Sat Oct 28 02:02:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544476, encodeId=576e15444e682, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Oct 25 11:02:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581463, encodeId=d1471581463bb, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Wed Oct 25 11:02:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255549, encodeId=0e1f25554943, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 24 08:00:12 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1659957, encodeId=d9a3165995e07, content=<a href='/topic/show?id=24e82545262' target=_blank style='color:#2F92EE;'>#代谢物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25452, encryptionId=24e82545262, topicName=代谢物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1225086772, createdName=旅苦化文_216, createdTime=Sat Oct 28 02:02:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544476, encodeId=576e15444e682, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Oct 25 11:02:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581463, encodeId=d1471581463bb, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Wed Oct 25 11:02:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255549, encodeId=0e1f25554943, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 24 08:00:12 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1659957, encodeId=d9a3165995e07, content=<a href='/topic/show?id=24e82545262' target=_blank style='color:#2F92EE;'>#代谢物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25452, encryptionId=24e82545262, topicName=代谢物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1225086772, createdName=旅苦化文_216, createdTime=Sat Oct 28 02:02:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544476, encodeId=576e15444e682, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Oct 25 11:02:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581463, encodeId=d1471581463bb, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Wed Oct 25 11:02:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255549, encodeId=0e1f25554943, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 24 08:00:12 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
    2017-10-25 HinsMax
  4. [GetPortalCommentsPageByObjectIdResponse(id=1659957, encodeId=d9a3165995e07, content=<a href='/topic/show?id=24e82545262' target=_blank style='color:#2F92EE;'>#代谢物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25452, encryptionId=24e82545262, topicName=代谢物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1225086772, createdName=旅苦化文_216, createdTime=Sat Oct 28 02:02:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544476, encodeId=576e15444e682, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Oct 25 11:02:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581463, encodeId=d1471581463bb, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Wed Oct 25 11:02:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255549, encodeId=0e1f25554943, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 24 08:00:12 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
    2017-10-24 1dd8c52fm63(暂无匿称)

    学习学习.了解了解

    0

相关资讯

Psychooncology:前列腺癌术后的社会约束和心理健康研究

之前的研究表明了社会约束(情绪表达障碍)也许是影响心理健康的一个风险因子。最近,有研究人员进行了旨在调查前列腺癌相关的前列腺术后社会约束和心理健康之间的关系的研究。研究包括了3478名包括同伴病人,这些病人参与了机器人腹腔镜前列腺切除术开放(LAPPRO)试验,并且该试验为一个前列腺癌的机器人协助的腹腔镜检查和耻骨后前列腺癌根治术的前瞻性、多中心比较研究,研究人员在该研究中利用了log-binom

PLoS One:前列腺癌诊断中的计算机辅助检测研究

通过多参数核磁共振成像(mpMRI)技术对前列腺癌(PCa)的诊断目前是计算机辅助检测(CAD)工具发展的挑战。一个创新性的软件(Watson ElementaryTM)能够获得前列腺癌诊断的高敏感性和特异性,同时可以获得与格林森等级的关系。最近,有研究人员在他们的医院MRI前列腺活检数据库中评估了该软件在自动化PCa诊断中的表现。研究人员回顾性的评估了来自79名且年龄在64.61±6.64岁老年

Redox Biol:研究发现薄荷醇可以不依赖于TRPM8降低癌细胞活力

薄荷醇是一种天然存在的单萜醇,具有显著的生物学特性,包括止痒、镇痛、防腐、抗炎和降温作用,薄荷醇诱发寒冷感觉的能力由冷敏感的TRPM8受体介导。

Sci Rep:胚胎特异性蛋白1(PLAC1)是抗体-药物结合治疗前列腺癌免疫疗法的潜在靶标

之前,有研究人员指出他们的发现强烈的支持了PLAC1可作为前列腺癌(PCa)免疫疗法靶标的想法。最近,他们制作并评估了基于抗胚胎特异性蛋白1(PLAC1)的抗体药物结合体(ADC)对前列腺癌的靶标免疫治疗。研究发现,前列腺癌细胞表达出了可观的PLAC1水平。PLAC1克隆抗体2H12C12在前列腺细胞中表现出了与重组PLAC1高度的反映力和对PLAC1的选择性识别,但是在阴性对照LS180细胞中并

临床试验希望为前列腺癌提供毒性较小的治疗

在过去的十年中,免疫疗法已经成为肿瘤学领域最有前途和创新的领域之一。免疫疗法的目标是利用患者自身的免疫系统对抗癌症。2010年,美国食品和药物管理局(FDA)批准了第一种癌症治疗疫苗sipuleucel - T(品牌名称来源),用于治疗前列腺癌。Roswell Park癌症研究所泌尿生殖医学临床主任Gurkamal Chatta博士说:"从那时起,已经有其他免疫治疗前列腺癌的临床试验,但是我们还没

Cancer Sci: ZIC5可作为前列腺癌和结肠癌细胞的生存因子

在癌症治疗方法中,对特异药物靶标的鉴定非常重要。最近,有研究人员鉴定了小脑5锌指蛋白(ZIC5)可作为促进黑色素瘤恶化的因素,具体是通过来源于血小板生长因子(PDGFD)的表达。然而,ZIC5在其他癌症中的角色仍旧大量未知。在研究中,研究人员确定了ZIC5在前列腺癌(PCa)和结肠癌(CRC)细胞中的角色。结果表明,ZIC5在CRC和去分化的PCa组织中高度表达,然而,在临近的正常组织中表达量极小

Baidu
map
Baidu
map
Baidu
map